Clinical Trial Update: A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression [Phase 3]

View source ↗

Summary

A Phase 3 study of esketamine nasal spray plus a standard antidepressant for treatment-resistant depression has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• SPRAVATO (ESKETAMINE HYDROCHLORIDE)

Snippet

Sponsor: Janssen-Cilag International NV | Conditions: Depressive Disorder, Treatment-Resistant | Phase 3 | Status: WITHDRAWN